Ask about this productRelated genes to: Ro60 antibody
- Gene:
- RO60 NIH gene
- Name:
- Ro60, Y RNA binding protein
- Previous symbol:
- SSA2, TROVE2
- Synonyms:
- Ro60
- Chromosome:
- 1q31.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-06-17
- Date modifiied:
- 2018-11-07
Related products to: Ro60 antibody
Related articles to: Ro60 antibody
- TAFRO syndrome is a rare hyperinflammatory disorder characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly. Its coexistence with Sjögren's disease has only been reported in isolated cases, and both conditions are thought to share a pathogenic pathway mediated by the activation of the IL-6/VEGF axis and the presence of anti-SSA/Ro60 autoantibodies. We present a 33-year-old woman with primary Sjögren's disease who fulfilled the 2016 ACR/EULAR criteria and developed anasarca, persistent fever, severe thrombocytopenia, and acute kidney injury due to thrombotic microangiopathy and tubulointerstitial nephritis. Despite receiving pulse therapy and high-dose glucocorticoids, she experienced progressive deterioration that required renal replacement therapy. Given the suspicion of TAFRO syndrome associated with a systemic inflammatory response, weekly subcutaneous tocilizumab was initiated, resulting in rapid improvement in her overall condition, resolution of anasarca, and complete recovery of renal function. This case highlights the rare overlap between TAFRO syndrome and Sjögren's disease, in which IL-6 activation plays a central role. The favorable response to IL-6 blockade emphasizes the importance of early recognition of this association and consideration of targeted therapies for refractory hyperinflammation. - Source: PubMed
Publication date: 2026/05/23
Uribe-Ruíz N AMurillo-Baquero NVargas-Camacho A FSantiago-Pacheco VTaborda-Murillo AMuñoz-Vahos C HGonzález-Naranjo L AVanegas-García A L - Autoantibodies directed against Telomerase RNA Ro y-RNAs and Vault RNAs Domain Family Member 2 (TROVE2)/Ro60 and Tripartite Motif 21 (TRIM21)/Ro52 are historically related to distinct SSA/Ro autoantigens. However, despite advances facilitating separate testing, these autoantibodies remain frequently confused resulting in a lack of clarity and precision in the literature. We conducted a systematic literature review to inform a Delphi process to achieve consensus on a clearer, harmonised nomenclature. - Source: PubMed
Publication date: 2026/05/14
Nikolic Roko P ABen-Chetrit EldadFritzler Marvin JBuhler Katherine AShokravi ArveenBarreth Nathan HChan Edward K LAndrade Luís E CLin MonicaGrewal JappnBuyon JillDamoiseaux JanLee Adrian Y SSteiner GünterMénard Henri ABoire GillesPruijn Ger J MReeves Westley HSatoh MinoruScofield R HalTebo Anne EWener MarkChoi May Y - We sought to leverage machine learning algorithms to identify the complex clinical and serological signature of anti-centromere antibody (ACA) positivity in Sjögren's syndrome (SS) patients. - Source: PubMed
Publication date: 2026/04/23
Zhu WenlongFang TingZhu XinchaoYang ZheWang JiayaoWang Xinchang - While Sjögren disease (SjD) overlap is known to modulate the clinical-serologic manifestations of other connective tissue diseases, the association with anti-synthetase syndrome (ASyS) has been seldom described in Caucasian cohorts. Anti-Ro52 autoantibodies, shared by both conditions, may blur early diagnostic attribution, particularly when glandular symptoms precede myositis-spectrum features. - Source: PubMed
Publication date: 2026/04/01
La Rocca GaetanoFerro FrancescoMorina GiuliaPilato AndreaBerardicurti OnorinaFulvio GiovanniCarli LindaVancheri CarloSambataro GianlucaMosca MartaBaldini Chiara - BackgroundInterstitial fibrosis and tubular atrophy (IFTA) are key predictors of renal outcomes in lupus nephritis (LN), but serologic markers that identify patients at higher risk for tubulointerstitial damage are poorly defined. Anti-Ro60 antibodies are associated with heightened systemic immune activation and worse renal outcomes in systemic lupus erythematosus, but their relationship to IFTA in LN is unknown.MethodsWe performed a retrospective cohort study of adults with biopsy-confirmed LN at a single academic center. Clinical data, autoantibody profiles, and renal histopathology were abstracted from the medical record at or near the time of kidney biopsy. Ro60 status was determined by standard clinical immunoassays. IFTA severity was graded by a renal pathologist as none, mild, moderate, or severe. Ordinal logistic regression was used to evaluate the association between Ro60 positivity and IFTA severity. A multivariable proportional odds model included Ro60 positivity (primary exposure), Black race (the only variable with < 0.05 in the univariable analysis), and ISN/RPS class IV LN (an a priori clinical risk factor for fibrosis). Sensitivity analyses included dichotomizing IFTA (absent/mild vs moderate/severe), excluding the single severe IFTA case, and restricting to Black patients.ResultsForty-one patients met the inclusion criteria; 16 (39%) were Ro60-positive, and 25 (61%) were Ro60-negative. Ro60-positive patients were more often Black and had lower C3 and C4 levels; the distribution of LN classes was similar between groups. In univariable analysis, Ro60 positivity was associated with higher odds of more severe IFTA (OR 3.05; 95% CI 0.86-11.5; = 0.087), while Black race was strongly associated with worse IFTA (OR 7.82; 95% CI 1.02-93.12; = 0.014). In the multivariable model limited to 29 complete cases, Ro60 positivity remained associated with higher IFTA severity (OR 2.76; 95% CI 0.77-13.04; = 0.127), and Black race remained the strongest predictor (OR 8.06; 95% CI 0.92-275.61; = 0.015); class IV LN was not significantly associated with IFTA (OR 1.90; 95% CI 0.37-13.24; = 0.371). In a sensitivity analysis excluding the single patient with severe IFTA, the association between Ro60 positivity and IFTA strengthened (OR 5.25; = 0.028), and Black race remained strongly associated with worse IFTA (OR 15.79; = 0.005).ConclusionsIn this biopsy-based LN cohort, Ro60 positivity was associated with a consistent trend toward more severe IFTA, with a statistically significant association in sensitivity analysis excluding one severe outlier case. Black race was the most robust predictor of IFTA severity, highlighting persistent racial disparities in LN-related kidney damage. These findings support the hypothesis that anti-Ro60 antibodies contribute to tubulointerstitial injury and suggest that Ro60 status may help identify LN patients at higher risk for chronic structural damage. Larger, prospective studies are needed to confirm these associations and clarify the prognostic role of Ro60 in LN. - Source: PubMed
Publication date: 2026/04/16
Timlin HomaKoiral AbbalRosenber AviAdisa OluwadamilolaAtta Mohamed GKamel IhabGross MatthewDasgupta AlanaGeetha Duvuru